nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—Fluid overload—Carboplatin—esophageal cancer	0.0274	0.0659	CcSEcCtD
Dexmedetomidine—Infarction—Capecitabine—esophageal cancer	0.0133	0.0319	CcSEcCtD
Dexmedetomidine—Sinus tachycardia—Capecitabine—esophageal cancer	0.00913	0.022	CcSEcCtD
Dexmedetomidine—Hypophosphataemia—Cisplatin—esophageal cancer	0.00859	0.0207	CcSEcCtD
Dexmedetomidine—Generalised oedema—Cisplatin—esophageal cancer	0.00839	0.0202	CcSEcCtD
Dexmedetomidine—Fluid overload—Cisplatin—esophageal cancer	0.00802	0.0193	CcSEcCtD
Dexmedetomidine—Disorder sight—Capecitabine—esophageal cancer	0.00773	0.0186	CcSEcCtD
Dexmedetomidine—Pneumothorax—Capecitabine—esophageal cancer	0.00739	0.0178	CcSEcCtD
Dexmedetomidine—Infection—Carboplatin—esophageal cancer	0.00603	0.0145	CcSEcCtD
Dexmedetomidine—Hypomagnesaemia—Capecitabine—esophageal cancer	0.00579	0.0139	CcSEcCtD
Dexmedetomidine—Nephropathy—Methotrexate—esophageal cancer	0.00575	0.0139	CcSEcCtD
Dexmedetomidine—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00561	0.0135	CcSEcCtD
Dexmedetomidine—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00545	0.0131	CcSEcCtD
Dexmedetomidine—Laryngeal pain—Capecitabine—esophageal cancer	0.0054	0.013	CcSEcCtD
Dexmedetomidine—Haemoglobin decreased—Capecitabine—esophageal cancer	0.00534	0.0129	CcSEcCtD
Dexmedetomidine—Neuralgia—Capecitabine—esophageal cancer	0.00529	0.0128	CcSEcCtD
Dexmedetomidine—Pain—Carboplatin—esophageal cancer	0.00519	0.0125	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Cisplatin—esophageal cancer	0.0049	0.0118	CcSEcCtD
Dexmedetomidine—Wheezing—Cisplatin—esophageal cancer	0.00485	0.0117	CcSEcCtD
Dexmedetomidine—Pleural effusion—Capecitabine—esophageal cancer	0.0048	0.0116	CcSEcCtD
Dexmedetomidine—Body temperature increased—Carboplatin—esophageal cancer	0.0048	0.0116	CcSEcCtD
Dexmedetomidine—Fluid retention—Cisplatin—esophageal cancer	0.00474	0.0114	CcSEcCtD
Dexmedetomidine—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00458	0.011	CcSEcCtD
Dexmedetomidine—Rigors—Capecitabine—esophageal cancer	0.00451	0.0109	CcSEcCtD
Dexmedetomidine—Extrasystoles—Capecitabine—esophageal cancer	0.00437	0.0105	CcSEcCtD
Dexmedetomidine—Hypoxia—Methotrexate—esophageal cancer	0.00431	0.0104	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00404	0.00974	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Capecitabine—esophageal cancer	0.00402	0.00968	CcSEcCtD
Dexmedetomidine—Renal failure acute—Cisplatin—esophageal cancer	0.00392	0.00945	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.00368	0.00886	CcSEcCtD
Dexmedetomidine—Pleural effusion—Methotrexate—esophageal cancer	0.00358	0.00861	CcSEcCtD
Dexmedetomidine—Fluid retention—Capecitabine—esophageal cancer	0.00349	0.00841	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Cisplatin—esophageal cancer	0.0033	0.00794	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00326	0.00786	CcSEcCtD
Dexmedetomidine—Apnoea—Methotrexate—esophageal cancer	0.00323	0.00778	CcSEcCtD
Dexmedetomidine—Abnormal vision—Capecitabine—esophageal cancer	0.00321	0.00773	CcSEcCtD
Dexmedetomidine—Sepsis—Capecitabine—esophageal cancer	0.00319	0.00769	CcSEcCtD
Dexmedetomidine—Speech disorder—Methotrexate—esophageal cancer	0.00318	0.00767	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00307	0.00739	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00306	0.00736	CcSEcCtD
Dexmedetomidine—Sweating increased—Cisplatin—esophageal cancer	0.00305	0.00735	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00301	0.00725	CcSEcCtD
Dexmedetomidine—Oliguria—Methotrexate—esophageal cancer	0.00297	0.00716	CcSEcCtD
Dexmedetomidine—Renal failure acute—Capecitabine—esophageal cancer	0.00289	0.00697	CcSEcCtD
Dexmedetomidine—Atrial fibrillation—Capecitabine—esophageal cancer	0.00282	0.00679	CcSEcCtD
Dexmedetomidine—Thirst—Capecitabine—esophageal cancer	0.00281	0.00676	CcSEcCtD
Dexmedetomidine—Respiratory failure—Methotrexate—esophageal cancer	0.00279	0.00672	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00275	0.00663	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Cisplatin—esophageal cancer	0.00274	0.00659	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00274	0.00659	CcSEcCtD
Dexmedetomidine—Bradycardia—Cisplatin—esophageal cancer	0.00255	0.00614	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Capecitabine—esophageal cancer	0.00254	0.00612	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Methotrexate—esophageal cancer	0.00244	0.00587	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Capecitabine—esophageal cancer	0.00243	0.00585	CcSEcCtD
Dexmedetomidine—Visual impairment—Cisplatin—esophageal cancer	0.00241	0.00582	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.0024	0.00579	CcSEcCtD
Dexmedetomidine—Sepsis—Methotrexate—esophageal cancer	0.00238	0.00572	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00235	0.00567	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Cisplatin—esophageal cancer	0.00233	0.0056	CcSEcCtD
Dexmedetomidine—Abdominal distension—Capecitabine—esophageal cancer	0.00232	0.0056	CcSEcCtD
Dexmedetomidine—Bronchospasm—Capecitabine—esophageal cancer	0.00227	0.00547	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00226	0.00544	CcSEcCtD
Dexmedetomidine—Sweating increased—Capecitabine—esophageal cancer	0.00225	0.00541	CcSEcCtD
Dexmedetomidine—Arrhythmia—Cisplatin—esophageal cancer	0.00224	0.00539	CcSEcCtD
Dexmedetomidine—Malnutrition—Cisplatin—esophageal cancer	0.00218	0.00525	CcSEcCtD
Dexmedetomidine—Renal failure acute—Methotrexate—esophageal cancer	0.00215	0.00519	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00208	0.00501	CcSEcCtD
Dexmedetomidine—Pneumonia—Capecitabine—esophageal cancer	0.00207	0.00498	CcSEcCtD
Dexmedetomidine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00203	0.00489	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00202	0.00486	CcSEcCtD
Dexmedetomidine—Myocardial infarction—Capecitabine—esophageal cancer	0.00202	0.00486	CcSEcCtD
Dexmedetomidine—Anaemia—Cisplatin—esophageal cancer	0.00202	0.00486	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Capecitabine—esophageal cancer	0.002	0.00482	CcSEcCtD
Dexmedetomidine—Convulsion—Cisplatin—esophageal cancer	0.00189	0.00455	CcSEcCtD
Dexmedetomidine—Bradycardia—Capecitabine—esophageal cancer	0.00188	0.00453	CcSEcCtD
Dexmedetomidine—Haemoglobin—Capecitabine—esophageal cancer	0.00186	0.00447	CcSEcCtD
Dexmedetomidine—Anxiety—Cisplatin—esophageal cancer	0.00185	0.00446	CcSEcCtD
Dexmedetomidine—Haemorrhage—Capecitabine—esophageal cancer	0.00185	0.00445	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Capecitabine—esophageal cancer	0.00182	0.00438	CcSEcCtD
Dexmedetomidine—Visual impairment—Capecitabine—esophageal cancer	0.00178	0.00429	CcSEcCtD
Dexmedetomidine—Infection—Cisplatin—esophageal cancer	0.00177	0.00426	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00174	0.0042	CcSEcCtD
Dexmedetomidine—Tachycardia—Cisplatin—esophageal cancer	0.00174	0.00419	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00172	0.00415	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Capecitabine—esophageal cancer	0.00171	0.00413	CcSEcCtD
Dexmedetomidine—Angiopathy—Capecitabine—esophageal cancer	0.00168	0.00404	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00166	0.00401	CcSEcCtD
Dexmedetomidine—Hypotension—Cisplatin—esophageal cancer	0.00166	0.00401	CcSEcCtD
Dexmedetomidine—Chills—Capecitabine—esophageal cancer	0.00166	0.00399	CcSEcCtD
Dexmedetomidine—Arrhythmia—Capecitabine—esophageal cancer	0.00165	0.00397	CcSEcCtD
Dexmedetomidine—Mental disorder—Capecitabine—esophageal cancer	0.00162	0.0039	CcSEcCtD
Dexmedetomidine—Malnutrition—Capecitabine—esophageal cancer	0.00161	0.00387	CcSEcCtD
Dexmedetomidine—Dyspnoea—Cisplatin—esophageal cancer	0.00159	0.00382	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—esophageal cancer	0.00154	0.00371	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00154	0.0037	CcSEcCtD
Dexmedetomidine—Pain—Cisplatin—esophageal cancer	0.00152	0.00367	CcSEcCtD
Dexmedetomidine—Anaemia—Capecitabine—esophageal cancer	0.00149	0.00358	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Cisplatin—esophageal cancer	0.00147	0.00353	CcSEcCtD
Dexmedetomidine—Body temperature increased—Cisplatin—esophageal cancer	0.00141	0.00339	CcSEcCtD
Dexmedetomidine—Hypertension—Capecitabine—esophageal cancer	0.00139	0.00334	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—esophageal cancer	0.00138	0.00333	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—esophageal cancer	0.00138	0.00331	CcSEcCtD
Dexmedetomidine—Anxiety—Capecitabine—esophageal cancer	0.00136	0.00329	CcSEcCtD
Dexmedetomidine—Dry mouth—Capecitabine—esophageal cancer	0.00134	0.00322	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—esophageal cancer	0.00133	0.00319	CcSEcCtD
Dexmedetomidine—Confusional state—Capecitabine—esophageal cancer	0.00132	0.00319	CcSEcCtD
Dexmedetomidine—Infection—Capecitabine—esophageal cancer	0.0013	0.00314	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00128	0.00309	CcSEcCtD
Dexmedetomidine—Tachycardia—Capecitabine—esophageal cancer	0.00128	0.00309	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—esophageal cancer	0.00128	0.00307	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00127	0.00306	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—esophageal cancer	0.00125	0.003	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00124	0.00298	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—esophageal cancer	0.00123	0.00297	CcSEcCtD
Dexmedetomidine—Hypotension—Capecitabine—esophageal cancer	0.00123	0.00295	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cisplatin—esophageal cancer	0.00122	0.00293	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—esophageal cancer	0.0012	0.0029	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—esophageal cancer	0.0012	0.00288	CcSEcCtD
Dexmedetomidine—Dyspnoea—Capecitabine—esophageal cancer	0.00117	0.00282	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00113	0.00273	CcSEcCtD
Dexmedetomidine—Vomiting—Cisplatin—esophageal cancer	0.00113	0.00273	CcSEcCtD
Dexmedetomidine—Rash—Cisplatin—esophageal cancer	0.00112	0.0027	CcSEcCtD
Dexmedetomidine—Pain—Capecitabine—esophageal cancer	0.00112	0.0027	CcSEcCtD
Dexmedetomidine—Constipation—Capecitabine—esophageal cancer	0.00112	0.0027	CcSEcCtD
Dexmedetomidine—Dermatitis—Cisplatin—esophageal cancer	0.00112	0.0027	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—esophageal cancer	0.00111	0.00266	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Capecitabine—esophageal cancer	0.00108	0.0026	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00107	0.00258	CcSEcCtD
Dexmedetomidine—Nausea—Cisplatin—esophageal cancer	0.00106	0.00255	CcSEcCtD
Dexmedetomidine—Abdominal pain—Capecitabine—esophageal cancer	0.00104	0.0025	CcSEcCtD
Dexmedetomidine—Body temperature increased—Capecitabine—esophageal cancer	0.00104	0.0025	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—esophageal cancer	0.00104	0.0025	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—esophageal cancer	0.000985	0.00237	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—esophageal cancer	0.000971	0.00234	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000957	0.0023	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000944	0.00227	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—esophageal cancer	0.000913	0.0022	CcSEcCtD
Dexmedetomidine—Diarrhoea—Capecitabine—esophageal cancer	0.000898	0.00216	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—esophageal cancer	0.000871	0.0021	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—esophageal cancer	0.000868	0.00209	CcSEcCtD
Dexmedetomidine—Dizziness—Capecitabine—esophageal cancer	0.000868	0.00209	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000843	0.00203	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—esophageal cancer	0.000835	0.00201	CcSEcCtD
Dexmedetomidine—Vomiting—Capecitabine—esophageal cancer	0.000834	0.00201	CcSEcCtD
Dexmedetomidine—Rash—Capecitabine—esophageal cancer	0.000827	0.00199	CcSEcCtD
Dexmedetomidine—Dermatitis—Capecitabine—esophageal cancer	0.000827	0.00199	CcSEcCtD
Dexmedetomidine—Headache—Capecitabine—esophageal cancer	0.000822	0.00198	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—esophageal cancer	0.000805	0.00194	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000799	0.00192	CcSEcCtD
Dexmedetomidine—Nausea—Capecitabine—esophageal cancer	0.00078	0.00188	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—esophageal cancer	0.000772	0.00186	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—esophageal cancer	0.000772	0.00186	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—esophageal cancer	0.000668	0.00161	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—esophageal cancer	0.000646	0.00156	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—esophageal cancer	0.000621	0.0015	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—esophageal cancer	0.000616	0.00148	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—esophageal cancer	0.000615	0.00148	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—esophageal cancer	0.000612	0.00147	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—esophageal cancer	0.00058	0.0014	CcSEcCtD
Dexmedetomidine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000115	0.000197	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GNG7—esophageal cancer	0.000115	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—EP300—esophageal cancer	0.000115	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—NOS3—esophageal cancer	0.000115	0.000196	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALDH2—esophageal cancer	0.000114	0.000195	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH3—esophageal cancer	0.000114	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—GHRL—esophageal cancer	0.000114	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH2—esophageal cancer	0.000113	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PSME2—esophageal cancer	0.000112	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PSME1—esophageal cancer	0.000112	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ANXA1—esophageal cancer	0.000112	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FBXW7—esophageal cancer	0.000112	0.000191	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000111	0.00019	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000111	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	0.000111	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ENO1—esophageal cancer	0.000111	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS1—esophageal cancer	0.000111	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PSME1—esophageal cancer	0.000111	0.000189	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PSME2—esophageal cancer	0.000111	0.000189	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ANXA1—esophageal cancer	0.00011	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.00011	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00011	0.000188	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PSME2—esophageal cancer	0.000109	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PSME1—esophageal cancer	0.000109	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP19A1—esophageal cancer	0.000109	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SST—esophageal cancer	0.000109	0.000186	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTT1—esophageal cancer	0.000109	0.000186	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALDH2—esophageal cancer	0.000108	0.000184	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP2A6—esophageal cancer	0.000107	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—EP300—esophageal cancer	0.000107	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SST—esophageal cancer	0.000107	0.000183	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000107	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—GHRL—esophageal cancer	0.000106	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH3—esophageal cancer	0.000106	0.000181	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—GHRL—esophageal cancer	0.000104	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH3—esophageal cancer	0.000104	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FBXW7—esophageal cancer	0.000104	0.000178	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000104	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	0.000104	0.000178	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FBXW7—esophageal cancer	0.000103	0.000176	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTT1—esophageal cancer	0.000102	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH2—esophageal cancer	0.000102	0.000174	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ENO1—esophageal cancer	0.000102	0.000174	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS1—esophageal cancer	0.000102	0.000174	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP2A6—esophageal cancer	0.000101	0.000173	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000101	0.000172	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PSME2—esophageal cancer	0.0001	0.000172	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PSME1—esophageal cancer	0.0001	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFBR2—esophageal cancer	0.0001	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—HMOX1—esophageal cancer	9.96e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.94e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TPI1—esophageal cancer	9.94e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	9.83e-05	0.000168	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	9.78e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ADH1B—esophageal cancer	9.75e-05	0.000167	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ENO1—esophageal cancer	9.6e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS1—esophageal cancer	9.6e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ABCB1—esophageal cancer	9.56e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALDOB—esophageal cancer	9.53e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH2—esophageal cancer	9.52e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SMAD4—esophageal cancer	9.48e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PSME2—esophageal cancer	9.46e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PSME1—esophageal cancer	9.46e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP1B1—esophageal cancer	9.43e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	9.37e-05	0.00016	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMP—esophageal cancer	9.31e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GAPDH—esophageal cancer	9.18e-05	0.000157	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	9.13e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	9.13e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CRABP1—esophageal cancer	9.09e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	9.09e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	9.06e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFBR2—esophageal cancer	9.04e-05	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP19A1—esophageal cancer	8.86e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SST—esophageal cancer	8.84e-05	0.000151	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALOX15—esophageal cancer	8.83e-05	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—EP300—esophageal cancer	8.71e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP1B1—esophageal cancer	8.66e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GNG7—esophageal cancer	8.65e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	8.62e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	8.62e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SMAD4—esophageal cancer	8.55e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—PIK3CA—esophageal cancer	8.5e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	8.48e-05	0.000145	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFBR2—esophageal cancer	8.44e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TPI1—esophageal cancer	8.42e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTO1—esophageal cancer	8.42e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	8.31e-05	0.000142	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.26e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—esophageal cancer	8.22e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP1B1—esophageal cancer	8.16e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP19A1—esophageal cancer	8.14e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALDH2—esophageal cancer	8.11e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—HMOX1—esophageal cancer	8.09e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALDOB—esophageal cancer	8.08e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SMAD4—esophageal cancer	7.99e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PIK3CA—esophageal cancer	7.94e-05	0.000136	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	7.86e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GAPDH—esophageal cancer	7.77e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ABCB1—esophageal cancer	7.76e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HIF1A—esophageal cancer	7.75e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	7.73e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.71e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CRABP1—esophageal cancer	7.7e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—esophageal cancer	7.68e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP19A1—esophageal cancer	7.67e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.62e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—HMOX1—esophageal cancer	7.43e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KDR—esophageal cancer	7.41e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GNG7—esophageal cancer	7.33e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ENO1—esophageal cancer	7.22e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.22e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ABCB1—esophageal cancer	7.13e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PSME1—esophageal cancer	7.12e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PSME2—esophageal cancer	7.12e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—HMOX1—esophageal cancer	7e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	7e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOTCH1—esophageal cancer	6.98e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.87e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALDH2—esophageal cancer	6.87e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	6.86e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ABCB1—esophageal cancer	6.72e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KDR—esophageal cancer	6.69e-05	0.000114	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	6.54e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTT1—esophageal cancer	6.53e-05	0.000112	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	6.49e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	6.46e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	6.45e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	6.44e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.43e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CREBBP—esophageal cancer	6.39e-05	0.000109	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CREBBP—esophageal cancer	6.33e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	6.31e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KDR—esophageal cancer	6.25e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—esophageal cancer	6.24e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—esophageal cancer	6.22e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	6.15e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.14e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ENO1—esophageal cancer	6.12e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS1—esophageal cancer	6.12e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PSME2—esophageal cancer	6.03e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PSME1—esophageal cancer	6.03e-05	0.000103	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—esophageal cancer	5.95e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	5.89e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	5.8e-05	9.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.78e-05	9.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—NOS3—esophageal cancer	5.72e-05	9.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	5.72e-05	9.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NOS3—esophageal cancer	5.67e-05	9.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	5.62e-05	9.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—esophageal cancer	5.4e-05	9.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	5.37e-05	9.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	5.34e-05	9.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	5.31e-05	9.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—esophageal cancer	5.3e-05	9.07e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.27e-05	9.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.27e-05	9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	5.26e-05	8.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	5.25e-05	8.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—esophageal cancer	5.23e-05	8.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.2e-05	8.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CREBBP—esophageal cancer	5.19e-05	8.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	5.17e-05	8.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	5.12e-05	8.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.08e-05	8.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	5.08e-05	8.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.06e-05	8.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	5.02e-05	8.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	4.94e-05	8.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	4.89e-05	8.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	4.88e-05	8.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	4.79e-05	8.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	4.78e-05	8.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	4.78e-05	8.18e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CREBBP—esophageal cancer	4.76e-05	8.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	4.71e-05	8.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—esophageal cancer	4.69e-05	8.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NOS3—esophageal cancer	4.65e-05	7.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	4.55e-05	7.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—esophageal cancer	4.53e-05	7.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CREBBP—esophageal cancer	4.49e-05	7.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	4.48e-05	7.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	4.47e-05	7.65e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HMOX1—esophageal cancer	4.46e-05	7.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	4.4e-05	7.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.38e-05	7.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—esophageal cancer	4.35e-05	7.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	4.34e-05	7.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—esophageal cancer	4.31e-05	7.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.29e-05	7.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NOS3—esophageal cancer	4.27e-05	7.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	4.26e-05	7.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—esophageal cancer	4.25e-05	7.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	4.23e-05	7.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	4.09e-05	7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	4.07e-05	6.97e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NOS3—esophageal cancer	4.02e-05	6.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	3.95e-05	6.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—esophageal cancer	3.9e-05	6.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	3.89e-05	6.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	3.89e-05	6.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	3.88e-05	6.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	3.82e-05	6.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	3.76e-05	6.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—esophageal cancer	3.76e-05	6.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	3.7e-05	6.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—esophageal cancer	3.68e-05	6.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—esophageal cancer	3.68e-05	6.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—esophageal cancer	3.64e-05	6.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	3.63e-05	6.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	3.58e-05	6.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—esophageal cancer	3.53e-05	6.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	3.39e-05	5.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.38e-05	5.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	3.32e-05	5.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—esophageal cancer	3.24e-05	5.55e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.24e-05	5.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—esophageal cancer	3.22e-05	5.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	3.21e-05	5.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—esophageal cancer	3.19e-05	5.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—esophageal cancer	3.17e-05	5.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	3.12e-05	5.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	3.11e-05	5.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	3.1e-05	5.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—esophageal cancer	3.09e-05	5.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—esophageal cancer	3.06e-05	5.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	3.05e-05	5.22e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.03e-05	5.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	2.95e-05	5.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	2.88e-05	4.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CREBBP—esophageal cancer	2.86e-05	4.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	2.79e-05	4.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.77e-05	4.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	2.69e-05	4.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	2.65e-05	4.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	2.61e-05	4.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—esophageal cancer	2.6e-05	4.45e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	2.57e-05	4.4e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NOS3—esophageal cancer	2.56e-05	4.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	2.56e-05	4.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	2.52e-05	4.31e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—esophageal cancer	2.4e-05	4.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.35e-05	4.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—esophageal cancer	2.3e-05	3.94e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—esophageal cancer	2.26e-05	3.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	2.19e-05	3.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	2.11e-05	3.62e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—esophageal cancer	1.95e-05	3.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.7e-05	2.91e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.44e-05	2.47e-05	CbGpPWpGaD
